▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Recent Articles by Brian Orelli, PhD

Money Pills

Nov 22, 2016 by Brian Orelli, PhD

What Happened in Biotech in 2016?

Lessons from the year give biotech investors clues on what to look for next year.

Doctor Patient 2

Nov 17, 2016 by Brian Orelli, PhD

Better Buy: Juno Therapeutics vs. bluebird bio

A battle of two platform drugmakers.

scientist research laboratory

Nov 14, 2016 by Brian Orelli, PhD

Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today

Seeming anything -- including preclinical data -- will spark shares of the beaten-down biotech.

Doctor and Patient

Nov 14, 2016 by Brian Orelli, PhD

Why Corbus Pharmaceuticals Holdings Inc. Skyrocketed Higher Today

Positive phase 2 data from the small biotech sends shares higher.

Infant

Nov 11, 2016 by Brian Orelli, PhD

Ionis Pharmaceuticals Inc Back in the Black (for Now)

The biotech produces positive earnings, but to stay there it's going to have to get some more drugs approved.

Anthrax

Nov 10, 2016 by Brian Orelli, PhD

Emergent Biosolutions Inc Slimmed Down, Waiting on Contract

After shedding its biologics division, the biodefense specialist waits for final details of its contract with the U.S. government to sell its anthrax vaccine.

Pills

Nov 9, 2016 by Brian Orelli, PhD

Why These Biotechs Are Soaring Today

Investors believe a Trump presidency is better for the biotech industry than a Clinton one would have been.

Sickle red blood cells

Nov 9, 2016 by Brian Orelli, PhD

727.6 Million Reasons bluebird bio Inc. Has Time to Figure It Out

The biotech has enough cash to work out the problems with its gene therapy process.

Money Pills

Nov 9, 2016 by Brian Orelli, PhD

Why These Biotechs Saw Double-Digit Gains Today

Investors re-evaluate biotechs' valuations now that Hilary Clinton won't be president.

Doctor Chest X-ray

Nov 8, 2016 by Brian Orelli, PhD

Why Cempra Inc Fell Over the Last 2 Days

FDA uncertainty plagues the biotech's share price.

Money Pills

Nov 8, 2016 by Brian Orelli, PhD

Why Celldex Therapeutics, Inc. Jumped Higher Today

Investors are warming up to Celldex's newest acquisition.

Increasing drug sales

Nov 7, 2016 by Brian Orelli, PhD

Exelixis, Inc. Continues Its Solid Launch

The biotech's kidney cancer drug, Cabometyx, is off to a good start in its first full quarter on the market.

Money Pills

Nov 7, 2016 by Brian Orelli, PhD

Why Horizon Pharma PLC Jumped Higher Today

A solid third-quarter earnings report has the drugmaker's shares heading higher.

Todler running

Nov 7, 2016 by Brian Orelli, PhD

Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today

More positive phase 3 data for its SMA drug Spinraza sends shares of the biotech soaring.

Scientist in lab

Nov 4, 2016 by Brian Orelli, PhD

Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data

Lopsided deaths in the biotech's clinical trial testing revusiran led to discontinuation of the drug's development, but investors need more data to be comfortable with the rest of the company's pipeline.

Multiple Sclerosis

Nov 4, 2016 by Brian Orelli, PhD

Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales

Third-quarter earnings were solid, but 2017 is setting up to be an inflection point for the drugmaker.

CabometyxHorixontal

Nov 4, 2016 by Brian Orelli, PhD

Why Exelixis, Inc. Reported Higher Today

The biotech continues its solid launch of its kidney cancer drug Cabometyx.

Doctor Computer

Nov 3, 2016 by Brian Orelli, PhD

Genomic Health, Inc.: Almost at Breakeven

The cancer-test maker reports solid third-quarter results on its way to breakeven.

Qiagen GeneReader

Nov 3, 2016 by Brian Orelli, PhD

Qiagen NV Jumps After Beating Its Earnings Guidance

The scientific-test maker registers a solid third quarter.

Sickle red blood cells

Nov 3, 2016 by Brian Orelli, PhD

Why bluebird bio Inc. Got Knocked Down Today

The biotech falls on data released ahead of next month's American Society of Hematology meeting.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services